The primary role of protooncogene c-kit in mast cell differentiation is supported by the development of mast cells from CD34 ϩ /CD117 ϩ (c-kit) myeloid precursors. Growth factor independence, neoplastic transformation and differentiation of mast cells were found in association with c-kit activating mutations in both murine and human mastocytoma and mast cell diseases. We have identified a novel c-kit mutation (D816Y) in peripheral blood mononuclear cells from a patient with AML (M2), massive presence of mast cells in bone marrow and rapid progression of the disease. The mutation, a G=T transversion at nt 2467 of the c-kit gene resulting in Asp816=Tyr substitution, corresponds to the D814Y and D817Y mutations identified and characterized in the murine P815 mastocytoma and the rat RBL-2H3 mast cell leukemia cell lines. The absence of SCF transcripts that we found by RTPCR in the patient's blasts indicates that, also in humans, this activating mutation leads to SCF independent growth. The expression of the mutant allele on Kit signaling may be further enhanced by trisomy of chromosome 4 (carrying the c-kit gene) in the patient's blasts. From these findings it is concluded that mast cells could be generated from a leukemic CD34/CD117-positive clone, that combines the antigenic expression of mast cell precursor to the growth and differentiation factor-independence which was derived by the c-kit D816Y mutation.
INTRODUCTION
Receptor tyrosine kinases (RTKs) mediate cellular response to a broad array of extracellular signals involved in the regulation of cell proliferation and differentiation (1, 2) . The KIT RTK, encoded by the c-kit proto-oncogene, is a member of type III RTK subfamily as the receptors for platelet-derived growth factor (PDGFR) and colony-stimulating factor-1 (CSF-1R). The characteristics of this RTK subfamily consist of an extracellular domain with five Ig-like repeats, a transmembrane domain, and a bipartite intracellular tyrosine kinase domain. Binding of the ligand, SCF (Stem Cell Factor), promotes KIT dimerization and transphosphorylation at specific tyrosine residues that can serve as high-affinity docking sites for intracellular proteins with Src homology 2 (SH2) domains (3) . The SCF/KITmediated signaling is crucial for proliferation, differentiation and survival of hematopoietic stem cells and derived mast cells (4) (5) (6) (7) (8) . C-kit is expressed in a low fraction (about 4%) of bone marrow stem cells: CD34 ϩ /CD117 ϩ myeloid precursors are known to be the progenitors of mast cells (9, 10) . Mechanisms disrupting the fine coupling of ligand binding and receptor activation are known to underlie leukemogenesis (11) (12) (13) (14) . Loss of growth factor control of leukemic progenitor cells may be caused by autocrine/ paracrine production of SCF by leukemic blasts expressing the KIT receptor (15) and activating c-kit mutations (13, 14, (16) (17) (18) . Two point mutations, Val560-Gly and Asp816-Val, in the c-kit intracellular TK domain have been identified in a human mastocytic leukemia cell line (12, 13) , and the latter has also been found in a human mast cell neoplasm (19) . Interestingly, c-kit exon 17, harbouring the Asp816-Val mutation shared by the above tumors, appears to be also the site of identical germline/somatic mutations in patients with mastocytosis associated with hematological disorders (17, 19) and a nearby mutation (Asp820-Gly) in aggressive mast cell disease (18) . Comprehension of the functional effects of the activating c-kit mutations in man may be greatly facilitated by previous findings on the murine mutations, such as Val559-Gly corresponding to human Val560-Gly and Asp814-Val corresponding to human Asp816-Val (13, 20) . We here report on a new c-kit mutation, Asp816-Tyr, affecting a different nucleotide of the same codon involved in the HMC-1 human mast cell leukemia line (12, 13) and human mastocytosis (17, 19) . This novel mutation has been identified in blasts from a patient with AML M 2 leukemia with mast cell involvement and rapid progression of the disease. It strictly corresponds to the D814Y mutation identified in the mouse mastocytoma cell line p815 and fully characterized in its biological and functional effects (16, 21) . Disease progression in the patient confirms the unfavorable prognosis which has been attributed to myeloid leukemia characterized by mast cell lineage involvement and factor-independent differentiation of mast cells (11) . The overall clinical, cytogenetic and molecular results presented converge in pointing out that differentiation of mast cells occurred in vivo in the patient's CD34 ϩ /CD117 ϩ myeloid blasts, which acquired a pattern of ligandindependent growth and differentiation through the activating c-kit mutation.
MATERIALS AND METHODS

Immunophenotypic Analysis by Flow Cytometry
Peripheral blood and/or bone marrow mononucleate cells were isolated on Ficoll-Hypaque gradient and labeled for immuno phenotypic assay carried out by a FACSCalibur Becton Dickinson flow cytometer. We included in our panel the monoclonal antibodies HPCA-1 (Becton Dickinson), that recognizes hematopoietic progenitor cells and most of leukemic blasts, and 95C3 (Immunotech, Marseille, France), that recognizes an extracellular epitope of c-kit receptor. Positivity was defined as Ն20% of stained leukemic blasts.
SCF RT-PCR
cDNA was synthesized from total RNA of mononucleate cells from peripheral blood/bone marrow with random primer of an AMV reverse transcriptase kit (Promega, Madison, WI, USA). cDNA was then subjected to PCR to amplify the 505 bp of DNA fragment between nucleotide 199 and 703 of human SCF cDNA using sense (5Ј-ACTTGGATTCTCATTGCATTT-3Ј) and antisense (5Ј-CTTTCTCAGGACTTAATG TTGAAG-3Ј) specific primers. DNA fragments were generated during 30 cycles of PCR (denaturation at 94 for 30Љ, annealing at 55 for 30Љ and extension at 72 for 30Љ). PCR products were examined on 1.5% agarose gel with lambda DNA digested with HindIII as size marker.
Denaturing Gradient Gel Electrophoresis (DGGE)
c-Kit exons 11, 12, 13, 14, 18, 19, 20 were amplified by using the primer pairs and conditons published by Spritz et al (22) . Exon 17 was amplified using primers having the following sequences: sense: 5Ј-AGTTTTCACTCTT-TACA AG-3Ј; antisense: 5Ј-clamp-TGTCAAG-CAGAGAA TGGGT-3Ј . DNA fragments from exon 17 were generated during 25 cycles (denaturation at 94C for 25 sec, annealing at 55C for 25 sec, extension at 72C for 25 sec, and a final extension of 5 min). One primer, either 5Ј-or 3Ј-, of each set was designed to contain a 40-nucleotide GC clamp. The introduction of a GC-clamp into the amplified fragment allows nearly 100% detection rate of any base change within the fragment (23) . The PCR products obtained with the GC-clamped ampliprimers were analyzed by DGGE (24) . The DGGE apparatus was from D GENE system (Biorad Lab., Hercules, CA, USA). Perpendicular gradient gels were prepared with 10% acrylamide-bisacrylamide (37,5:1) in TAE (40mM tris Acetate/1mM EDTA, pH8) and by varying denaturant concentrations (100% denaturant corresponds to 7M urea and 40% formamide). Melting maps of exons were generated with the MacMelt software (Biorad Lab., Hercules, CA, USA ) which calculates the melting temperature (Tm) of each exon as a function of its nucleotide sequence and composition. Translation of the calculated melting temperature into a range of denaturing agents gives a rough indication for the DGGE-gel conditions. The range of denaturant gradient was different and specific for each amplified exon. GC-clamped PCR-products of exon 17 were run through 10% polyacrylamide gel containing a gradient from 0 to 50% of denaturing agents. Gels were run in TAE at 56C, 130V for 5 hrs. After electrophoresis, gels were stained with 0.4 mg/ml ethidium bromide for 10 min, visualized using an UV transilluminator, and photographed using Polaroid type 55 film. Subsequently, GC-clamped PCR-products of exon 17 were run through a Constant Denaturing Gel (CDGE) at 37% as specific denaturing percentage, in TAE at 56C, 130V for 14 hrs. The concentration of denaturant used for CDGE is determined at the maximum split between wildtype and mutant DNA, as seen in the perpendicular denaturing gel.
Sequence Analysis
The PCR products of genomic DNA were obtained using the same primers of DGGE analysis without the GC-clamp. Amplified DNA fragments of exon 17 which had an abnormal mobility by DGGE analysis were sequenced directly according to Circum Vent(exo-)Kit procedures (New England Biolabs, Beverly, MA), using 5Ј-33 P-endlabeled primers. Sequencing reaction products were electrophoresed on 6% polyacrylamide-7M urea gels in TBE (45mM Tris borate/1 mM EDTA, pH 8.0) for 2 hrs at 55 mA. Gels were then fixed for 20 min in 12% methanol and 10% acetic acid, dried and exposed to ␤-MAX films (Amersham, Milan Italy).
Kit RT-PCR
Kit cDNA was subjected to PCR to amplify the 683bp of DNA fragment between nucleotide 1804 and 2486 using the sense primer (5Ј CTGGGTGCTGGAGCTTT 3Ј, nt 1804-1820) and the mutagenic antisense (5Ј TTAGAATCATTCTT-GACGT 3Ј, nt 2468-2486 with a C substituting the T at position 2484). PCR conditions were the following: after 5Ј denaturation at 94 samples were subjected to 30 cycles (denaturation at 94C for 20Љ, annealing at 53C for 20Љ and extension at 72C for 20Љ and a final extension at 72C for 7Љ). PCR amplification was performed using 5Ј-33 Pend-labeled sense primer. Following BsaHI digestion the normal and the mutant allele could be resolved by 6% polyacrylamide-7M urea gels in TBE (45mM Tris borate/1 mM EDTA, pH 8.0) for 4 hrs at 55 mA.
RESULTS
Clinical Findings and Course of Disease
The patient, a 47-years old man, was admitted into our department because of leucocytosis (WBC 46x10 9 /L; differential count: Neutrophils 20%, Lymphocytes 17%, Monocytes 4%, Myelocytes 3%, Blasts 66%) and a platelet count of 14x10 9 oxidase) and SBB (Sudan black). The pattern of reactivity of bone marrow cells with MoAbs was: DR (94%), CD34 (87%), CD13 (87%), CD33 (70%), CD15 (47%), CD117 (23%). CD3, CD7, CD19, CD10 and TdT were negative (Table 1) . Cytogenetic analysis of bone marrow aspirate at diagnosis showed a 47XY, t(8;21) (q22;q22) ϩ4 karyotype in all 27 metaphases which could be analyzed. Routine blood chemistry was normal. The patient was initially treated with two courses of Idarubicin, VP16 and ARA-C followed by two courses of Mitoxantron and high-dose ARA-C, resulting in morphologic partial remission. An increased number of mast cells was documented in the bone marrow biopsy (Figure1b). One month later the patient experienced a dramatic leukemic regrowth, was unresponsive to chemotherapy, and died 23 months after diagnosis.
Absence of SCF Transcript in Mononuclear Cells from PB and BM
To determine whether the expansion of mast cells observed both in bone marrow (Figure1, a) and peripheral blood was induced by SCF stimulation via an autocrine mechanism, the expression of SCF transcript was examined by RT-PCR analysis. Figure 2 shows that SCF transcripts were not detected in leukemic blasts from both BM and PB, whereas the expected 505-bp fragment (nucleotides 199 to 703) was easily detected in the SCF expressing HL-60 cell line included as a positive control. This finding indicates that the massive mast cell growth and differentiation observed in the patient's bone marrow is not dependent on SCF stimulation.
DGGE Analysis of c-kit Gene and Sequence Analysis
Genomic DNA from PB mononucleate cells was amplified by primers specific for exons 10 to 14 and 16 to 20, which span the intracellular domain of the KIT receptor. DGGE analysis of the GC-clamped PCR products was performed allowing the identification of a variant in exon 17 that was then characterized by DNA sequencing (Figure 3) . The CDGE band pattern also contained the wild-type allele as shown by heteroduplexes and homoduplexes bands (Figure 3, upper panel) . Following direct sequencing of the amplified c-kit exon 17, a heterozygous G=T transversion was detected at nucleotide 2467 of codon 816 (GAC=TAC) in the phosphotrans-ferase domain. This point mutation leads to a drastic aminoacid change, i.e., substitution of Tyr 816 for Asp. Nucleotide sequence in the region of the c-kit mutation was confirmed by sequencing both the coding and non-coding strands of the product. The observed mutation is novel in human and corresponds to the murine D814Y described in P-815 murine mastocytoma cell line (16) and rat D817Y mutations identified in RBL-2H3 rat mast cell leukemia cell line (25) .
Expression of the Mutated c-kit Allele
PCR amplification of kit cDNA by using the mutagenic primer described (see Materials and Methods) allowed to introduce a BsaHI site (GPu/ CGPyC) into the 683 bp fragment from the normal 
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Myeloperoxidase ϩ allele. The normal and the mutated allele could thus be distinguished as only the PCR product from the normal allele was cut by BsaHI into fragments of 665 and 18 bp (data not shown). This test confirmed that the mutant c-kit allele was expressed in the patient's blasts
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DISCUSSION
An activating c-kit mutation, involving a substitution of tyrosine for aspartic acid in the phosphotransferase domain (D814Y) has been already described in the mouse mastocytoma cell line P815 (16) . Discussion of the functional consequences of this mutation is needed because of its perfect equivalence with the D816Y mutation here identified in a patient with acute myeloid leukemia and peculiar mast cell involvement. Expression of the mutant D814Y KIT receptor was shown to lead to the degradation, through the ubiquitindependent proteolytic pathway, of a 65-kDa protein identified as the src homology domain 2 (SH2)-containing protein tyrosine phosphatase SHP-1 (26) . It has been established that protein tyrosine phosphatase SHP1 directly dephosphorylates and negatively regulates c-Kit in cell typespecific manner (3). The D814Y mutation also altered the sites of receptor autophosphorylation and peptide substrate selectivity, thus activating the oncogenic potential of Kit with a novel synergyc mechanism. It is likely that the human corresponding Asp=Tyr substitution may be endowed with a similar oncogenic potential due to the evolutionary identity of signaling pathway through the kit receptor (26) . Direct evidences on the role of the D816Y mutation on progression of the leukemia in the carrier patient can be drawn from the joined molecular and clinical data. The absence of SCF transcripts, observed by RTPCR in the mutant blasts confirms that proliferation of the leukemic clone is not dependent on SCF stimulation. Expression of the mutant c-kit allele was demonstrated by cDNA amplification using a mutagenic primer tailored on the normal allele. Furthermore, chromosome 4 trisomy, which was recorded in the blast karyotype, strongly suggests a dosage effect for this activating mutation. The peculiar combination of this rare numerical abnormality with the t(8;21) translocation, found in a percentage of AML M2 patients ranging from 18 to 40% (27) , was present in all leukemic blasts. It is thus tempting to speculate that the t(8;21) conferred to a kit-expressing myeloid blast the proliferative capability, while the c-kit activating mutation was superimposed and selected by non disjunction of the chromosome carrying the mutated allele. The significance of increased dosage of a chromosome bearing a mutated protooncogene has been underlined for trisomy 7, and met activating mutations in hereditary renal carcinomas (28) . Demonstration that non-random duplication of the chromosome 7 carrying a mutated Ha-ras-1 allele is a major mechanism by which a mutated gene is over-represented was obtained in mouse skin tumors (29) . The spontaneous, ligandindependent differentiation of mast cells from a CD34 ϩ CD117 ϩ myeloid clone previously documented in vitro 11 is here observed in vivo (Figure1) and associated with the specific c-kit D816Y mutation. Last by, all activating c-kit mutations identified so far in hereditary or somatic diseases are associated with abnormal mast cell growth and differentiation and map within exon 17 (13, (17) (18) (19) , which thus appears to be a crucial domain for c-kit control of mast cell lineage.
